Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple malignancies, especially in non-small cell lung cancer (NSCLC). With the extensive application of ICIs in clinical practice, clinicians have to manage their toxicities, which are often termed immune-related adverse eve...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ke Cheng, Yuqing Wang, Yuwen Zhou, Ruolan Xia, Liansha Tang, Jiyan Liu
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ff2063d2011a4056bf89759ae4b179b4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ff2063d2011a4056bf89759ae4b179b4
record_format	dspace
spelling	oai:doaj.org-article:ff2063d2011a4056bf89759ae4b179b42021-12-01T00:04:52ZNeurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development1179-554910.1177/11795549211056261https://doaj.org/article/ff2063d2011a4056bf89759ae4b179b42021-11-01T00:00:00Zhttps://doi.org/10.1177/11795549211056261https://doaj.org/toc/1179-5549Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple malignancies, especially in non-small cell lung cancer (NSCLC). With the extensive application of ICIs in clinical practice, clinicians have to manage their toxicities, which are often termed immune-related adverse events (irAEs). Several ICIs, such as nivolumab, pembrolizumab, atezolizumab, and durvalumab, have been approved by the US Food and Drug Administration (FDA) to treat advanced NSCLC, accompanied by a broad spectrum of toxicity reactions. However, ICIs-associated neurological toxicities, regarding polyneuropathy, Bell palsy, encephalopathy, and myasthenia gravis, as uncommon emerging toxicities have not been well recognized, present a challenge for clinicians to improve awareness of supervision, recognition, and management before death from them. Herein, we have summarized the incidence, diagnosis, clinical manifestations, potential mechanisms, treatments, and outcomes of ICIs-related neurotoxicity and optimized the management approach for NSCLC patients. Prompt recognition and proper management are indispensable to reduce the morbidity of these patients with immune-related neurological toxicities.Ke ChengYuqing WangYuwen ZhouRuolan XiaLiansha TangJiyan LiuSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENClinical Medicine Insights: Oncology, Vol 15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ke Cheng Yuqing Wang Yuwen Zhou Ruolan Xia Liansha Tang Jiyan Liu Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
description	Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple malignancies, especially in non-small cell lung cancer (NSCLC). With the extensive application of ICIs in clinical practice, clinicians have to manage their toxicities, which are often termed immune-related adverse events (irAEs). Several ICIs, such as nivolumab, pembrolizumab, atezolizumab, and durvalumab, have been approved by the US Food and Drug Administration (FDA) to treat advanced NSCLC, accompanied by a broad spectrum of toxicity reactions. However, ICIs-associated neurological toxicities, regarding polyneuropathy, Bell palsy, encephalopathy, and myasthenia gravis, as uncommon emerging toxicities have not been well recognized, present a challenge for clinicians to improve awareness of supervision, recognition, and management before death from them. Herein, we have summarized the incidence, diagnosis, clinical manifestations, potential mechanisms, treatments, and outcomes of ICIs-related neurotoxicity and optimized the management approach for NSCLC patients. Prompt recognition and proper management are indispensable to reduce the morbidity of these patients with immune-related neurological toxicities.
format	article
author	Ke Cheng Yuqing Wang Yuwen Zhou Ruolan Xia Liansha Tang Jiyan Liu
author_facet	Ke Cheng Yuqing Wang Yuwen Zhou Ruolan Xia Liansha Tang Jiyan Liu
author_sort	Ke Cheng
title	Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
title_short	Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
title_full	Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
title_fullStr	Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
title_full_unstemmed	Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
title_sort	neurological adverse events induced by immune checkpoint inhibitors in non-small cell lung cancer: current perspectives and new development
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/ff2063d2011a4056bf89759ae4b179b4
work_keys_str_mv	AT kecheng neurologicaladverseeventsinducedbyimmunecheckpointinhibitorsinnonsmallcelllungcancercurrentperspectivesandnewdevelopment AT yuqingwang neurologicaladverseeventsinducedbyimmunecheckpointinhibitorsinnonsmallcelllungcancercurrentperspectivesandnewdevelopment AT yuwenzhou neurologicaladverseeventsinducedbyimmunecheckpointinhibitorsinnonsmallcelllungcancercurrentperspectivesandnewdevelopment AT ruolanxia neurologicaladverseeventsinducedbyimmunecheckpointinhibitorsinnonsmallcelllungcancercurrentperspectivesandnewdevelopment AT lianshatang neurologicaladverseeventsinducedbyimmunecheckpointinhibitorsinnonsmallcelllungcancercurrentperspectivesandnewdevelopment AT jiyanliu neurologicaladverseeventsinducedbyimmunecheckpointinhibitorsinnonsmallcelllungcancercurrentperspectivesandnewdevelopment
_version_	1718406181393793024

Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development

Ejemplares similares